Assessing a Height Artificial Intelligence Algorithm to Estimate Height of Children (INFER)

February 2, 2026 updated by: Danone Asia Pacific Holdings Pte, Ltd.

A Study to Collect Data to Build Artificial INtelligence Derived Algorithms For Estimating Height and Weight in childRen (INFER)

An exploratory study to explore the possibility of using computer vision algorithms to estimate a child's height using images taken by a healthcare professional or parents.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This is an exploratory, observation, data-collection study that aims to evaluate the performance of a Height Artificial Intelligence (HAI) algorithm in a real world setting. Images will be collected by parents or healthcare professionals, together with physical height measurements. This data will be used to evaluate the accuracy of the algorithm and to explore potential improvements. Data on the acceptance and experience of using the algorithm will be collected for improvements.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
250

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • Singapore
      • Singapore, Singapore
        • KK Women's and Children's Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Children aged above 24 months old and below 6 years of age with no physical deformities

Description

Inclusion Criteria:

  • Children aged above 24 months old and below 6 years old.
  • Parent(s) should have access to the internet and a smartphone or table to complete study questionnaires, take images and upload images.
  • Parent(s) should be able to comprehend the content of the study and complete the study questionnaires in English.
  • Written consent from parents and/or legally acceptable representative

Exclusion Criteria:

  • Children who are unable to stand upright against a wall
  • Children who are unable to cooperate with standing height measurement

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Children aged above 24 months old and below 6 years of age
Children aged above 24 months old and below 6 years of age with no structural abnormalities of the lower limbs or orthopaedic conditions
Other: Physical height measurement
Physical height will be measured and images will be collected for AI to estimate the height

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Accuracy of the height AI (cm)
Time Frame: 2 days

Accuracy of the Height AI (cm) in a clinic and in a home setting, derived from:

  1. The height AI prediction from images collected
  2. The physical height measurements of subjects using WHO standard height measurement
2 days

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Accuracy of the Weight AI (kg)
Time Frame: 2 days

Accuracy of the Weight AI (kg) in a clinic and in a home setting, derived from:

  1. The weight prediction from the standing images collected in this study
  2. The WHO standard weight measurement of subjects
2 days

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Assessments by the parent on usability of the AI in a home-setting via study questionnaire
Time Frame: 2 days
  1. Ease of collecting images (very easy to very difficult)
  2. Acceptable range of height & weight difference between AI prediction & WHO measurement (between ≤1cm and >5cm)
  3. Frequency of measuring child's height & weight at home (never,< 1/month, at least <1/month, at least 1 per 2 weeks,at least 1/week,> 1/week,daily)
  4. Usefulness of using digital tool to measure child's height & weight at home (Very useful to Not very useful)
  5. Frequency of using digital tool to measure child's height & weight at home (never,<1/month, at least 1/month, at least 1 per 2 weeks,at least 1/week,>1/week,daily)
  6. Likelihood and reason of using a digital tool to measure child's height & weight at home (Very Likely to Very unlikely)
  7. Sharing the child's height & weight measured using digital tool with others (Very Likely to Very unlikely)
  8. Use of mobile apps to track child's height & weight (free text)
  9. Other features/tools useful to measure child's height & weight (free text)
2 days
Assessments by the investigator on usability of the AI in a clinic-setting via a questionnaire
Time Frame: 2 days
  1. Acceptable range of height and weight difference between the height and weight AI from the WHO measurement (≤ 1cm, ≤ 2cm, ≤ 3cm, ≤ 4cm, ≤5cm, >5cm)
  2. Likelihood of using a digital tool to measure a child's height and weight in a clinical setting (Very Likely, Likely, Neutral, Unlikely, Very unlikely)
  3. Likelihood of recommending parents to use a digital tool to measure their child's height and weight in a clinical setting (Very Likely, Likely, Neutral, Unlikely, Very unlikely)
  4. Other features/tools they find useful to measure the child's height and weight (free text)
2 days
Assessments by the investigator on ease of collecting images in a clinic-setting via a questionnaire
Time Frame: 2 days
Investigator's assessment on the ease of collecting the images [Very Easy, Easy, Normal, Difficult, Very Difficult]
2 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Danone Asia Pacific Holdings Pte, Ltd.

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
KK Women's and Children's Hospital

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Fabian Yap, MBBS, KK Women's and Children's Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 9, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 4, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 4, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 5, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 27, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 29, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
February 4, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 2, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • SBB20R&31696-A

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings